NovaQuest

Divided by asset class, Alternatives Watch tracked about $3.6 billion in private market deals announced in the week ending Jan. 13, 2023.

Divided by asset class, Alternatives Watch tracked a total of roughly $5.6 billion in alternative investment deals announced in the week ending Oct. 28.

The following is a compilation of the private market deal activity for the week ending July 22. Divided by asset class, Alternatives Watch tracked a total of roughly $4.5 billion in deals publicly announced in the five-day period. Private equity: $2.6 billion ...

NovaQuest Private Equity held the final close of its second fund at $500 million after less than seven months of fundraising. Like the firm’s preceding fund that started to deploy capital 2018, NovaQuest Private Equity Fund II is managed by ...

NovaQuest Capital Management expanded is royalty pipeline with a deal to support development of German pharmaceutical firm Grünenthal's lead asset, the osteoarthritis product candidate resiniferatoxin (RTX). Under the newly announced deal, NovaQuest will reimburse Grünenthal’s investments into late-stage studies of ...

The State of Wisconsin Investment Board in Madison approved $4.4 billion in fresh capital commitments across hedge funds, private equity and real estate at the tail end of 2021, according to recent board meeting materials. The $166 billion fund, which ...

NovaQuest’s partners have found an interesting way to invest in pharmaceuticals at a time when neither the focus on healthcare nor the potential for treatment of rare diseases have been greater. “We are investing in the late stages of R&D ...

Azurity Pharmaceuticals entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors, including JW Asset Management and KKR. Azurity Pharmaceuticals was born as a corporate identity in June 2019 with the acquisition of Silvergate Pharmaceuticals by CutisPharma. NovaQuest ...